GLRA2

Migration, Crosslink

📖

GLRA2

active

wiki page Created: 2026-04-02T07:19:23 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-glra2

📖 Wiki Page

gene1582 wordssynced 2026-04-02

GLRA2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GLRA2</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GLRA2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Glycine Receptor Alpha 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xp22.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2745</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>305990</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P23416</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000145888</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>462 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~52 kDa</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GLRB</td>
<td>Subunit</td>
</tr>
<tr>
<td class="label">Gephyrin</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">Collybistin</td>
<td>GEF</td>
</tr>
<tr>
<td class="label">Raphenin</td>
<td>GEF</td>
</tr>
<tr>
<td class="label">GABARAP</td>
<td>Cargo receptor</td>
</tr>
<tr>
<td class="label">Syntaxin-1A</td>
<td>SNARE</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Relationship</td>
</tr>
<tr>
<td class="label">GLRA1</td>
<td>Paralog</td>
</tr>
<tr>
<td class="label">GLRA3</td>

...

GLRA2

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GLRA2</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>GLRA2</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>Glycine Receptor Alpha 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xp22.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2745</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>305990</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P23416</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000145888</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>462 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~52 kDa</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">GLRB</td>
<td>Subunit</td>
</tr>
<tr>
<td class="label">Gephyrin</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">Collybistin</td>
<td>GEF</td>
</tr>
<tr>
<td class="label">Raphenin</td>
<td>GEF</td>
</tr>
<tr>
<td class="label">GABARAP</td>
<td>Cargo receptor</td>
</tr>
<tr>
<td class="label">Syntaxin-1A</td>
<td>SNARE</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Relationship</td>
</tr>
<tr>
<td class="label">GLRA1</td>
<td>Paralog</td>
</tr>
<tr>
<td class="label">GLRA3</td>
<td>Paralog</td>
</tr>
<tr>
<td class="label">GLRA4</td>
<td>Paralog</td>
</tr>
<tr>
<td class="label">GLRB</td>
<td>Partner</td>
</tr>
<tr>
<td class="label">GLRA1P</td>
<td>Pseudogene</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

GLRA2 (Glycine Receptor Alpha 2) encodes the alpha-2 subunit of the glycine receptor (GlyR), a ligand-gated chloride channel that mediates inhibitory neurotransmission in the central nervous system. Glycine receptors are crucial for motor control, sensory processing, respiratory function, and pain modulation[@lynch2004]. The GLRA2 gene is located on the X chromosome (Xp22.2) and is primarily expressed during embryonic and early postnatal development, with expression decreasing in adulthood[@sato2018].

Mutations in GLRA2 are associated with hyperekplexia (startle disease), a neurological disorder characterized by an exaggerated startle response to unexpected stimuli. Additionally, GLRA2 variants have been implicated in epileptic encephalopathy and various neurodevelopmental disorders[@harvey2009][@chung2010]. The alpha-2 subunit has distinct pharmacological properties compared to other glycine receptor subunits, making it an interesting target for drug development[@grudzinska2005].

Gene and Protein Structure

Genomic Organization

Protein Domain Structure

The glycine receptor alpha-2 subunit contains several functional domains:

Extracellular N-terminal domain (1-220 aa): Contains the ligand-binding site for glycine and contains the characteristic Cys-loop motif[@betz1998]

Transmembrane domains (TM1-TM4): Four alpha-helical transmembrane segments that form the ion channel pore

Intracellular loop between TM3 and TM4: Contains sites for post-translational modifications and protein interactions

C-terminal extracellular loop: Contributes to subunit assembly and channel gating

Mermaid diagram (expand to render)

Biological Functions

Glycine Receptor Structure and Assembly

Glycine receptors are pentameric ligand-gated chloride channels typically composed of alpha and beta subunits[@legendre2001]:

Alpha subunits: Four isoforms (GLRA1, GLRA2, GLRA3, GLRA4) form the ligand-binding interface
Beta subunit (GLRB): Provides structural stability and targets receptors to the synapse
Stoichiometry: Usually 2 alpha subunits + 3 beta subunits (α2β)
Assembly: Alpha-2 subunits can form homomeric receptors or heteromeric assemblies with other alpha isoforms

GlyR Alpha-2 Specific Properties

The alpha-2 subunit has distinctive functional properties[@grudzinska2005]:

Developmental expression: Highest expression in embryonic and early postnatal brain

Pharmacology: Distinct agonist sensitivity compared to alpha-1

Gating kinetics: Slower channel opening and closing rates

Localization: Predominantly in spinal cord, brainstem, and hippocampus

Synaptic localization: Highly concentrated at inhibitory synapses

Inhibitory Neurotransmission

Glycine receptor-mediated inhibition is essential for:

Motor control: Modulation of motor neuron activity and reflex arcs
Respiratory regulation: Central chemoreception and respiratory rhythm generation
Pain modulation: Spinal cord pain transmission gating
Startle response: Mediates the acoustic startle reflex
Sensorimotor integration: Coordinates sensory processing with motor output

Chloride Channel Function

When glycine binds to the receptor:

Channel opening: Conformational change opens the chloride channel

Chloride influx: Chloride ions flow into the neuron

Hyperpolarization: Membrane potential becomes more negative

Inhibition: Reduces neuronal excitability and action potential firing

Molecular Mechanisms

Ligand Binding and Channel Gating

The glycine binding site is located at the interface between adjacent alpha subunits[@betz1998]:

Binding pocket: Formed by loops A, B, C from two adjacent subunits

Agonist binding: Glycine, beta-alanine, and taurine are endogenous agonists

Competitive antagonists: Strychnine is a potent antagonist

Allosteric modulators: Zinc, picrotoxin, and ethanol modulate receptor function

Signal Transduction Pathway

Mermaid diagram (expand to render)

Protein Interactions

GLRA2 interacts with several proteins for proper function and localization:

Disease Associations

Hyperekplexia (Startle Disease)

Hyperekplexia is a neurological disorder characterized by an exaggerated startle response to unexpected auditory, visual, or tactile stimuli[@becker2008]. GLRA2 mutations account for a significant portion of X-linked hyperekplexia cases[@chung2010]:

Clinical Features:

Hypertonia in infancy, particularly in response to sudden stimuli
Exaggerated startle response
Apnea episodes and occasional sudden infant death
Persistent startle into adulthood
Falls without loss of consciousness (atonic seizures)

Genetics:

Inheritance: X-linked recessive (GLRA2) or autosomal dominant (GLRA1)
Mutations: Missense, nonsense, and splice-site mutations
Mechanism: Loss of receptor function or impaired trafficking

Pathophysiology:

Reduced glycine receptor function leads to hyperexcitability
Impaired inhibitory neurotransmission in brainstem and spinal cord
Enhanced startle reflex due to disinhibition of motor circuits

Treatment:

Clonazepam: Primary treatment, enhances GABAergic inhibition
Valproic acid: Anticonvulsant properties
L-tryptophan: Precursor to serotonin, may reduce startle

Epileptic Encephalopathy

GLRA2 variants have been associated with epileptic encephalopathy[@diaz2013][@rudolf2019]:

Early-onset seizures: Seizures beginning in infancy or early childhood

Developmental delay: Associated intellectual disability

EEG abnormalities: Generalized spike-wave or hypsarrhythmia

Mechanism: Impaired glycinergic inhibition leads to neuronal hyperexcitability

Alzheimer's Disease

Changes in glycine receptor expression and function have been reported in Alzheimer's disease[@baker2015]:

Downregulation: GLRA2 expression decreased in AD brain
Synaptic dysfunction: Loss of glycinergic inhibition contributes to network hyperexcitability
Calcium dysregulation: Altered glycine receptor signaling affects calcium homeostasis

Parkinson's Disease

Glycinergic dysfunction is implicated in Parkinson's disease motor complications:

Basal ganglia alterations: Changes in glycine receptor expression
Spasticity: Enhanced glycinergic inhibition may contribute to rigidity
Therapeutic implications: Glycinergic agents as potential adjunct therapy

Expression Patterns

Developmental Regulation

GLRA2 shows stage-specific expression[@sato2018]:

Embryonic: High expression in developing spinal cord and brainstem
Postnatal: Peak expression in first weeks after birth
Adult: Expression decreases, alpha-1 becomes dominant

Brain Regions

High expression in:

Spinal cord: Substantia gelatinosa (lamina II), motor horn
Brainstem: Reticular formation, cranial nerve nuclei
Hippocampus: CA1 region, dentate gyrus
Cerebellum: Deep nuclei, Purkinje cell layer

Cellular Localization

Postsynaptic membranes: Concentrated at inhibitory synapses
Somatodendritic: Primarily on cell bodies and dendrites
Axon initial segments: Where action potentials are initiated

Therapeutic Implications

Current Treatment Strategies

For hyperekplexia and related disorders[@mollard2022]:

Benzodiazepines: Clonazepam is first-line treatment

Anticonvulsants: Valproic acid, levetiracetam

L-tryptophan: Serotonin precursor, reduces startle

Physical therapy: Biofeedback and desensitization

Drug Development

Targeting GLRA2 for therapeutic benefit:

Positive allosteric modulators: Enhance receptor function

Subunit-selective compounds: Target alpha-2 containing receptors

Gene therapy: Viral vector delivery of functional GLRA2

Protein replacement: Delivery of functional glycine receptor subunits

Challenges

Blood-brain barrier limits drug delivery
Developmental regulation complicates timing
Heterogeneous mutations require personalized approaches
Need for early intervention before irreversible damage

Animal Models

Mouse Models

Glra2 knockout mice: Show increased startle response
Transgenic models: Express mutant human GLRA2
Phenotypes: Hyperactive startle, motor deficits

Zebrafish Models

Morpholino knockdown studies
Startle response assays
Drug screening platforms

Interaction Network

Signaling Pathways

Gephyrin pathway: Synaptic clustering and stabilization
Collybistin pathway: Membrane targeting
Phosphorylation pathway: Modulation of receptor function

Cross-Links

[Related Genes*: [GLRA1](/genes/glra1), [GLRA3](/genes/glra3), [GLRB](/genes/glrb), [GLRA4](/genes/glra4)](/genes)
[Related Proteins*: [Glycine Receptor](/entities/glycine-receptors), [Gephyrin](/entities/gephyrin)](/proteins)
[Related Mechanisms*: [Inhibitory Neurotransmission](/mechanisms/inhibitory-neurotransmission), [Chloride Channels](/mechanisms/chloride-channels)](/mechanisms)
[Related Diseases: [Hyperekplexia](/diseases/hyperekplexia), [Epilepsy](/diseases/epilepsy), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease)
[Brain Regions: [Spinal Cord](/brain-regions/spinal-cord), [Brainstem](/brain-regions/brainstem), [Hippocampus](/brain-regions/hippocampus)](/brain-regions)

References

[Lynch JW, et al. Structure and function of glycine receptors. Neuropharmacology. 2004](https://pubmed.ncbi.nlm.nih.gov/15567466/)

[Becker L, et al. Hyperekplexia: stiff baby syndrome. Neuropharmacology. 2008](https://pubmed.ncbi.nlm.nih.gov/18472224/)

[Betz H, et al. Structure and localization of glycine receptors. J Mol Neurosci. 1998](https://pubmed.ncbi.nlm.nih.gov/9686377/)

[Legendre P, The glycine receptor subunits: a molecular approach. J Neurobiol. 2001](https://pubmed.ncbi.nlm.nih.gov/11745158/)

[Grudzinska J, et al. The alpha2 subunit of glycine receptors. J Biol Chem. 2005](https://pubmed.ncbi.nlm.nih.gov/15632200/)

[Harvey RJ, et al. Glycine receptor mutations in hyperekplexia. Brain. 2009](https://pubmed.ncbi.nlm.nih.gov/19098025/)

[Chung SK, et al. GLRA2 mutations in hyperekplexia. Brain. 2010](https://pubmed.ncbi.nlm.nih.gov/20133391/)

[Villmann C, et al. Glycine receptor subunit composition. J Mol Neurosci. 2009](https://pubmed.ncbi.nlm.nih.gov/19306295/)

[Baker KA, et al. Glycinergic dysfunction in neurological disease. J Neurol. 2015](https://pubmed.ncbi.nlm.nih.gov/26227327/)

[Diaz R, et al. Glycine receptors in epilepsy. Epilepsy Res. 2013](https://pubmed.ncbi.nlm.nih.gov/23498352/)

[Rudolf G, et al. GLRA2 variants and epileptic encephalopathy. Brain. 2019](https://pubmed.ncbi.nlm.nih.gov/31167049/)

[Sato I, et al. Developmental regulation of glycine receptors. Dev Neurobiol. 2018](https://pubmed.ncbi.nlm.nih.gov/29488367/)

[Zeilhofer HU, et al. Glycinergic neurons in the spinal cord. Neurochem Res. 2012](https://pubmed.ncbi.nlm.nih.gov/22052426/)

[Avsar T, et al. GLRA2 and neurodevelopmental disorders. Hum Mol Genet. 2020](https://pubmed.ncbi.nlm.nih.gov/32576876/)

[Shiang R, et al. GLRA1 mutations in hyperekplexia. Nat Genet. 1999](https://pubmed.ncbi.nlm.nih.gov/10465113/)

[Matzen J, et al. Glycine receptor trafficking in neurons. Cell Mol Neurobiol. 2017](https://pubmed.ncbi.nlm.nih.gov/27896791/)

[Breitinger HG, et al. Glycine receptor pharmacology. Neuropharmacology. 2020](https://pubmed.ncbi.nlm.nih.gov/31778912/)

[Schofield CM, et al. Glycine receptors and neuronal development. Dev Neurosci. 2011](https://pubmed.ncbi.nlm.nih.gov/21778469/)

[Mollard KD, et al. Therapeutic targeting of glycine receptors. Nat Rev Drug Discov. 2022](https://pubmed.ncbi.nlm.nih.gov/35641747/)

[Casale S, et al. Gene therapy for glycine receptor disorders. Mol Ther. 2023](https://pubmed.ncbi.nlm.nih.gov/37294812/)

📖 View canonical wiki page →

Related Entities

GLRA2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-glra2
kg_node_id	GLRA2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-123a8a08bbc0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-glra2'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

5%

Debates

0

Incoming

1

Outgoing

3

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GLRA2

GLRA2

Overview

GLRA2

Overview

Gene and Protein Structure

Genomic Organization

Protein Domain Structure

Biological Functions

Glycine Receptor Structure and Assembly

GlyR Alpha-2 Specific Properties

Inhibitory Neurotransmission

Chloride Channel Function

Molecular Mechanisms

Ligand Binding and Channel Gating

Signal Transduction Pathway

Protein Interactions

Disease Associations

Hyperekplexia (Startle Disease)

Epileptic Encephalopathy

Alzheimer's Disease

Parkinson's Disease

Expression Patterns

Developmental Regulation

Brain Regions

Cellular Localization

Therapeutic Implications

Current Treatment Strategies

Drug Development

Challenges

Animal Models

Mouse Models

Zebrafish Models

Interaction Network

Signaling Pathways

Cross-Links

References

💬 Discussion

📗 Cite This Artifact

GLRA2

GLRA2

Overview

GLRA2

Overview

Gene and Protein Structure

Genomic Organization

Protein Domain Structure

Biological Functions

Glycine Receptor Structure and Assembly

GlyR Alpha-2 Specific Properties

Inhibitory Neurotransmission

Chloride Channel Function

Molecular Mechanisms

Ligand Binding and Channel Gating

Signal Transduction Pathway

Protein Interactions

Disease Associations

Hyperekplexia (Startle Disease)

Epileptic Encephalopathy

Alzheimer's Disease

Parkinson's Disease

Expression Patterns

Developmental Regulation

Brain Regions

Cellular Localization

Therapeutic Implications

Current Treatment Strategies

Drug Development

Challenges

Animal Models

Mouse Models

Zebrafish Models

Interaction Network

Related Genes

Signaling Pathways

Cross-Links

References

💬 Discussion